NasdaqGS:KURABiotechs
A Look at Kura Oncology’s Valuation Following KOMZIFTI’s FDA Approval for Relapsed AML
Kura Oncology recently attracted attention after KOMZIFTI, its once-daily oral menin inhibitor, secured full FDA approval for adults with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. This milestone addresses a treatment gap in AML care.
See our latest analysis for Kura Oncology.
Kura Oncology’s momentum has picked up meaningfully after KOMZIFTI’s approval, with the share price up over 48% in the past three months and 38% year-to-date. While recent investor...